Anti-PD-1/PD-L1 mAbs showed a benefit over chemotherapy in improving progression-free survival (PFS) and the overall response rate (ORR) of advanced melanoma patients with a relatively large effect size, supported by convincing evidence. Here, PDCD1 is linked to melanoma.